Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (636)	4/27/1998 12:22:00 AM
From: tom jones	Read Replies (2) \| Respond to of 834

To all: Questions about Texas Biotechnology. There was a news release 2-11-1998 about TBC11251 phase IIa being terminated so they can start larger trials for congestive heart failure. Has there been any more news on this? What phase? When? There was a news release 3-17-1997 giving the phase II results for Novastan used for acute myocardial infarction. What has happened with this? Is there a short position in TXB? Can someone give me the telephone number for investor relations? Tom

To: RXGOLF who wrote (636)	4/27/1998 1:23:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 834

RXGOLF - Refludan This is the recombinant form Hirudan, also recently approved for HIT. Reportedly very expensive - $1,400/day vs. $200 for Novastan. Also, 40% of patients develop allergies after one dose - then back to square one. Not too much of a threat.